Dipyridamole/aspirin combination in secondary stroke prevention: Effects on absolute myocardial blood flow and coronary vascular resistance

International Journal of Clinical Pharmacology and Therapeutics

Volumn 44, Issue 7, 2006, Pages 319-325

  Schaefer, W M ^a   Koch, K C ^a   Nowak, B ^a   Noth, J ^a   Buell, U ^a   Weiss, P H ^a  

^a UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

Author keywords

Aggrenox; Dipyridamole; Dipyridamole aspirin combination; Myocardial blood flow; Stroke

Indexed keywords

ACETYLSALICYLIC ACID; ACETYLSALICYLIC ACID PLUS DIPYRIDAMOLE; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ANTIDIABETIC AGENT; ANTILIPEMIC AGENT; BENSERAZIDE PLUS LEVODOPA; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENOXAPARIN; HEPARIN; METHOXY ISOBUTYL ISONITRILE TECHNETIUM TC 99M; NITRATE; OXYGEN 15;

ADULT; AGED; ARTICLE; BODY SURFACE; CEREBROVASCULAR ACCIDENT; CLINICAL ARTICLE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CORONARY VASCULAR RESISTANCE; CORRELATION ANALYSIS; FEMALE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE ENDDIASTOLIC VOLUME; HEART MUSCLE BLOOD FLOW; HEART MUSCLE ISCHEMIA; HUMAN; MALE; POSITRON EMISSION TOMOGRAPHY; SECONDARY PREVENTION; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; TRANSIENT ISCHEMIC ATTACK; TREATMENT DURATION; TREATMENT OUTCOME;

EID: 33745888056     PISSN: 09461965     EISSN: None     Source Type: Journal    
DOI: 10.5414/CPP44319     Document Type: Article

References (22)

1. Beleslin BD, Ostojic M, Stepanovic J, Djordjevic-Dikic A, Stojkovic S, Nedeljkovic M, Stankovic G, Petrasinovic Z, Gojkovic L, Vasiljevic-Pokrajcic Z. Stress echocardiography in the detection of myocardial ischemia: head-to-head comparison of exercise, dobutamine, and dipyridamole tests. Circulation. 1994; 90: 1168-1176.
2. Bergmann SR. Alert to physicians: possible interaction of aggrenox and adenosine. J Am Coll Cardiol. 2000; 36: 1432.
3. Chambers M, Hutton J, Gladman J. Cost-effectiveness analysis of antiplatelet therapy in the prevention of recurrent stroke in the UK. Aspirin, dipyridamole and aspirin-dipyridamole. Pharmacoeconomics. 1999; 16: 577-593 (published correction appears in Pharmacoeconomics. 2000; 17: 69).
4. Didisheim P. Inhibition by dipyridamole of arterial thrombosis in rats. Thromb Diath Haemorrh. 1968; 20: 257-266.
5. Diener HC, Cunha L, Forbes C, Sivenius J, Smets P, Lowenthal A. European Stroke Prevention Study 2. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke. J Neurol Sci. 1996; 143: 1-13.
6. Diener HC, Darius H, Bertrand-Hardy JM, Humphreys M. European Stroke Prevention Study 2. Cardiac safety in the European Stroke Prevention Study 2. Int J Clin Pract. 2001; 55: 162-163.
7. European Stroke Prevention. Study 2: efficacy and safety data. J Neurol Sci. 1997; 151 (Suppl): S1-S77.
8. Gamboa A, Ertl AC, Costa F, Farley G, Manier ML, Hachey DL, Diedrich A, Biaggioni I. Blockade of nucleoside transport is required for delivery of intraarterial adenosine into the interstitium: relevance to therapeutic preconditioning in humans. Circulation. 2003; 108: 2631-2635.
9. 15O blood pool scan. J Nucl Med. 1998; 39: 1696-1702.
10. 15O and dynamic positron-emission tomography: strategy for quantification in relation to the partial-volume effect. Circulation. 1988; 78: 104-115 (published correction appears in Circulation. 1988; 78: 1078).
11. Iida H, Rhodes CG, de Silva R, Araujo LI, Bloomfield PM, Lammertsma AA, Jones T. Use of the left ventricular time-activity curve as a noninvasive input function in dynamic oxygen-15-water positron emission tomography. J Nucl Med. 1992; 33: 1669-1677.
12. 15O-labeled water and PET. J Nucl Med. 1999; 40: 1848-1856.
13. Keltz TN, Innerfield M, Gitler B, Cooper JA. Dipyridamole-induced myocardial ischemia. JAMA. 1987; 257: 1515-1516.
14. Littmann L, Anderson JD, Monroe MH. Adenosine and Aggrenox: a hazardous combination. Ann Intern Med. 2002; 137: W1.
15. Mahony C, Wolfram KM, Cocchetto DM, Bjornsson TD. Dipyridamole kinetics. Clin Pharmacol Ther. 1982; 31: 330-338.
16. Marissal JP, Selke B, Amarenco P. Economic assessment of the secondary prevention of ischaemic stroke with dipyridamole plus aspirin (Aggrenox/ Asasantin) in France. Pharmacoeconomics. 2004; 22: 661-670.
17. Radvan J, Marwick TH, Williams MJ, Camici PG. Evaluation of the extent and timing of the coronary hyperemic response to dipyridamole: a study with transesophageal echocardiography and positron emission tomography with oxygen 15 water. J Am Soc Echocardiogr. 1995; 8: 864-873.
18. Schaefer WM, Koch KC, Kuehl H, Reinartz P, Kaiser H-J, vom Dahl J, Sabri O, Buell U, Nowak B. Effect of left ventricular volume and ejection on myocardial blood flow measured by oxygen-15 water positron emission tomography in coronary heart disease. Am J Cardiol. 2003; 91: 469-472.
19. 99mTc-MIBI SPECT: MRI validation and comparison of the emorycardiac toolbox with QGS and 4D-MSPECT. J Nucl Med. 2005; 46: 1256-1263.
20. Sivenius J, Cunha L, Diener HC, Forbes C, Laakso M, Lowenthal A, Smets P, Riekkinen P Sr. Second European Stroke Prevention Study: antiplatelet therapy is effective regardless of age. ESPS2 Working Group. Acta Neurol Scand. 1999; 99: 54-60.
21. Uren NG, Melin JA, De Bruyne B, Wijns W, Baudhuin T, Camici PG. Relation between myocardial blood flow and the severity of coronary artery stenosis. N Engl J Med. 1994; 330: 1782-1788.
22. Weiss HJ, Danese CA, Voleti CD. Prevention of experimentally induced arterial thrombosis by aspirin. Fed Proc. 1970; 29: 381.